Literature DB >> 22460809

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.

Michael C Haffner1, Johannes Laimer, Alcides Chaux, Georg Schäfer, Peter Obrist, Andrea Brunner, Irmgard E Kronberger, Klaus Laimer, Bora Gurel, Johann-Benedikt Koller, Christof Seifarth, Bettina Zelger, Helmut Klocker, Michael Rasse, Wolfgang Doppler, Neil H Bander.   

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed in prostate cancer as well as in the neo-vasculature of nonprostatic solid tumors. Here, we determined the expression pattern of PSMA in the vasculature of oral squamous cell carcinoma. Using a previously validated antibody, PSMA staining distribution and cyclooxygenase 2 (COX2) expression status was evaluated in a cohort of patients with squamous cell carcinoma of the oral cavity (n=96) using immunohistochemistry and was correlated with clinicopathological features as well as outcome. Twenty-four (25%) cases showed no detectable PSMA staining, 48 (50%) demonstrated positive immunoreactivity for PSMA in less than 50% of microvessels and 24 (25%) cases showed strong endothelial PSMA expression in more than 50% of tumor-associated microvessels. High endothelial PSMA expression was associated with greatly reduced survival (18.2 vs 77.3 months; P=0.0001) and maintained prognostic significance after adjusting for grade and stage in multivariate analysis (hazard ratio=2.19, P=0.007). Furthermore, we observed a strong association between endothelial PSMA and cancer cell-specific COX2 expression. In conclusion, we provide the first evidence for the prognostic significance of endothelial PSMA expression in oral squamous cell carcinoma and, suggest a potential interaction between arachidonic acid metabolites and endothelial PSMA expression in the tumor neo-vasculature.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460809     DOI: 10.1038/modpathol.2012.66

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  29 in total

1.  (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Authors:  Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03       Impact factor: 9.236

2.  Evaluation of 111In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen.

Authors:  Sangeeta Ray Banerjee; Vivek Kumar; Ala Lisok; Donika Plyku; Zora Nováková; Mary Brummet; Bryan Wharram; Cyril Barinka; Robert Hobbs; Martin G Pomper
Journal:  J Nucl Med       Date:  2018-09-20       Impact factor: 10.057

3.  Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.

Authors:  Sangeeta Ray Banerjee; Zhengping Chen; Mrudula Pullambhatla; Ala Lisok; Jian Chen; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2016-05-09       Impact factor: 4.774

Review 4.  Antibody-Drug Conjugates in Uro-Oncology.

Authors:  Dawid Sigorski; Paweł Różanowski; Ewa Iżycka-Świeszewska; Katarzyna Wiktorska
Journal:  Target Oncol       Date:  2022-05-14       Impact factor: 4.864

5.  Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.

Authors:  Sangeeta Ray Banerjee; Ethel J Ngen; Matthew W Rotz; Samata Kakkad; Ala Lisok; Richard Pracitto; Mrudula Pullambhatla; Zhengping Chen; Tariq Shah; Dmitri Artemov; Thomas J Meade; Zaver M Bhujwalla; Martin G Pomper
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-23       Impact factor: 15.336

Review 6.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

Review 7.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

8.  Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Chaitanya R Divgi; Eze A Wills; Lawrence Schwartz; Mithat Gönen; Peter Smith-Jones; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  EJNMMI Res       Date:  2015-04-29       Impact factor: 3.138

Review 9.  Abnormal COX2 protein expression may be correlated with poor prognosis in oral cancer: a meta-analysis.

Authors:  Zhi-Ming Wang; Jie Liu; Hong-Bo Liu; Ming Ye; Yu-Fei Zhang; Dong-Sheng Yang
Journal:  Biomed Res Int       Date:  2014-06-16       Impact factor: 3.411

10.  A molecular signature for the prediction of recurrence in colorectal cancer.

Authors:  Lisha Wang; Xiaohan Shen; Zhimin Wang; Xiuying Xiao; Ping Wei; Qifeng Wang; Fei Ren; Yiqin Wang; Zebing Liu; Weiqi Sheng; Wei Huang; Xiaoyan Zhou; Xiang Du
Journal:  Mol Cancer       Date:  2015-02-03       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.